- Home
- FE vs BDTX Comparison
FE vs BDTX Comparison
Compare FE & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FE | BDTX |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.6B | 116.8M |
| IPO Year | 2005 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FE | BDTX |
|---|---|---|
| Price | $51.00 | $2.16 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 6 |
| Target Price | ★ $49.27 | $10.20 |
| AVG Volume (30 Days) | ★ 3.9M | 585.3K |
| Earning Date | 05-22-2026 | 06-22-2026 |
| Dividend Yield | ★ 3.48% | N/A |
| EPS Growth | 3.53 | ★ 130.71 |
| EPS | ★ 1.76 | 0.39 |
| Revenue | ★ $15,090,000,000.00 | N/A |
| Revenue This Year | $2.52 | N/A |
| Revenue Next Year | $3.67 | N/A |
| P/E Ratio | $29.12 | ★ $5.72 |
| Revenue Growth | ★ 12.01 | N/A |
| 52 Week Low | $37.58 | $1.20 |
| 52 Week High | $52.02 | $4.94 |
Technical Indicators
Market Signals| Indicator | FE | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 60.90 | 43.58 |
| Support Level | $49.74 | $1.93 |
| Resistance Level | $51.39 | $2.86 |
| Average True Range (ATR) | 0.78 | 0.14 |
| MACD | -0.10 | -0.00 |
| Stochastic Oscillator | 57.58 | 38.84 |
Price Performance
Historical ComparisonAbout FE FirstEnergy Corp.
FirstEnergy is an investor-owned holding company with operations across five mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.